Yenidoğanın Epileptik Sendromları
Özet
Yenidoğan döneminde görülen epileptik sendromlar; selim idiyopatik konvülziyonlar, selim ailevi formlar, KCNQ2 ensefalopatisi ve nadir görülen DEND sendromu gibi çeşitli klinik tabloları kapsar. Bu hastalıkların çoğunda KCNQ2, KCNQ3, SCN2A ve SCN8A gibi genetik mutasyonlar temel etiyolojik faktör olarak öne çıkmaktadır. Tanı aşamasında klinik gözlem ve genetik testler belirleyici rol oynarken, tedavi süreci sendromun türüne göre fenobarbital, antiepileptikler veya sülfanilüre gibi spesifik yaklaşımları içerir. Prognoz, sendromun tipine göre değişiklik göstererek bazı vakalarda kendiliğinden düzelme sağlarken, bazılarında hayat boyu süren nörogelişimsel destek gerektirebilir.
Neonatal epileptic syndromes encompass various clinical conditions, ranging from benign idiopathic and familial convulsions to severe KCNQ2 encephalopathy and the rare DEND syndrome. Genetic mutations, specifically in genes such as KCNQ2, KCNQ3, SCN2A, and SCN8A, serve as the primary etiological drivers for the majority of these conditions. Diagnostic assessment relies on clinical presentation combined with genetic testing, while treatment strategies are tailored to the specific syndrome, utilizing options like antiepileptics or sulfonylurea therapy. Prognosis varies significantly depending on the underlying pathology, leading to spontaneous resolution in some benign cases or necessitating lifelong neurodevelopmental support in more severe forms.
Referanslar
Goldberg HJ, Sheehy EM. Fifth day fits: an acute zinc deficiency syndrome? Arch Dis Child 1982; 57:633.
Herrmann B, Lawrenz-Wolf B, Seewald C, et al. [5th day convulsions of the newborn infant in rotavirus infections]. Monatsschr Kinderheilkd 1993; 141:120.
Ishii A, Fukuma G, Uehara A, et al. A de novo KCNQ2 mutation detected in non-familial benign neonatal convulsions. Brain Dev 2009; 31:27.
Symonds JD, Elliot KS, Shetty J, Armstrong M, Brunklaus A, Cutcutache I, et al. Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants. Brain. 2021;144:2879–91.
Pressler RM, Cilio MR, Mizrahi EM, Moshe SL, Nunes ML, Plouin P, et al. The ILAE classification of seizures and the epilepsies: modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures. Epilepsia. 2021;62:615–28.
Sands TT, Balestri M, Bellini G, Mulkey SB, Danhaive O, Bakken EH, et al. Rapid and safe response to low-dose carbamazepine in neonatal epilepsy. Epilepsia. 2016;57:2019–30.
Cornet MC, Morabito V, Lederer D, Glass HC, Ferrao Santos S, Numis AL, et al. Neonatal presentation of genetic epilepsies: early differentiation from acute provoked seizures. Epilepsia. 2021;62:1907–20.
Dehan M, Quillerou D, Navelet Y, et al. [Convulsions in the fifth day of life: a new syndrome?]. Arch Fr Pediatr 1977; 34:730.
Mizrahi EM, Clancy RR. Neonatal seizures: early-onset seizure syndromes and their consequences for development. Ment Retard Dev Disabil Res Rev 2000;6(4):229–41.
Ronen GM, Penney S, Andrews W. The epidemiology of clinical neonatal seizures in Newfoundland: a population-based study. J Pediatr 1999;134(1):71–5.
Soldovieri MV, Boutry-Kryza N, Milh M, et al. Novel KCNQ2 and KCNQ3 mutations in a large cohort of families with benign neonatal epilepsy: first evidence for an altered channel regulation by syntaxin-1A. Hum Mutat 2014;35(3):356–67.
Ronen GM, Rosales TO, Connolly M, et al. Seizure characteristics in chromosome 20 benign familial neonatal convulsions. Neurology 1993;43(7):1355–60.
Heron SE, Crossland KM, Andermann E, et al. Sodium-channel defects in benign familial neonatal-infantile seizures. Lancet 2002;360(9336):851–2
Herlenius E, Heron SE, Grinton BE, et al. SCN2A mutations and benign familial neonatal-infantile seizures: the phenotypic spectrum. Epilepsia 2007;48(6):1138–42.
Weckhuysen S, Mandelstam S, Suls A, et al. KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. Ann Neurol 2012;71(1):15–25.
Numis AL, Angriman M, Sullivan JE, et al. KCNQ2 encephalopathy: delineation of the electroclinical phenotype and treatment response. Neurology 2014;82(4):368–70.
Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005; 54:2503.
